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Abstract
Introduction—Tissue factor (TF) is a potent initiator of the extrinsic coagulation cascade. The
role and source of TF in venous thrombotic disease is not clearly defined. Our study objective was
to identify the contribution of myeloid cell TF to venous thrombogenesis in mice.
Materials and Methods—The mouse electrolytic inferior vena cava model was used to induce
thrombosis. The following groups of mice were used (1) TFflox/floxLysMCre+ mice that have
reduced TF expression in myeloid cells, (2) TFflox/floxLysMCre- littermate controls, (3) Wild type
mice given a monoclonal anti-mouse TF antibody (1H1) to inhibit TF activity, and (4) Wild type
mice given rat IgG. Evaluations at baseline, day 2, and day 6 post thrombosis included thrombus
weight, vein wall inflammatory cell migration, vein wall TF mRNA, and plasma D-dimer levels.
Results—Inhibition of TF significantly decreased thrombus weight 2 days post venous
thrombosis. In contrast, TFflox/floxLysMCre+ had no change in thrombus weight when compared
to littermate controls. The absence of myeloid cell TF did not affect infiltration of neutrophils or
monocytes into the vein wall. TF mRNA expression in the vein wall decreased at 2 days but then
returned to baseline levels by 6 days post thrombosis. D-dimer levels peaked at 2 days post
thrombosis in mice with or without myeloid cell TF.
Conclusions—TF is important in the formation of venous thrombi in the macrovasculature.
However, TF expression by myeloid cells does not significantly contribute to venous
thrombogenesis in this model.
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Deep vein thrombosis (DVT) and pulmonary embolism, collectively known as venous
thromboembolism, are major health problems in the United States. With over 900,000 cases
and greater than 300,000 deaths each year, it is a significant cause of morbidity and
mortality [1]. Furthermore, 30% of those patients initially treated for DVT develop a
recurrence within 10 years [2, 3]. Understanding the underlying pathophysiology of venous
thrombus formation, propagation, and recurrence is essential to developing earlier diagnostic
assays, preventative therapies, and treatments.
Studies have shown that tissue factor (TF) plays a role in venous thrombosis [4-6]. TF is a
transmembrane glycoprotein that initiates the coagulation cascade. After vessel injury, TF
under the endothelium is exposed to the vascular lumen and serves as a cellular receptor for
plasma factor VII/VIIa. Together, the factor VIIa:TF complex activates factor X and factor
IX. Activated factor Xa in association with its cofactor Va, the prothrombinase complex,
cleaves prothrombin to thrombin, which in turn cleaves fibrinogen to fibrin. Then,
transglutaminase factor XIII cross-links fibrin to stabilize the thrombi [7]. TF is typically
expressed by perivascular cells [8-10] and tissues that need additional hemostatic protection,
like the heart (cardiac myocytes) [11], kidney (glomerular epithelial cells) [9], and brain
(astrocytes) [9, 11-14]. Unlike all other components of the clotting system, little or no active
TF is present in circulation in healthy individuals. The vessel wall [5, 6, 15] and
hematopoietic cells [4, 5, 16] have been postulated as major and minor sources of TF,
respectively that could participate in the initiation of venous thrombosis.
Endothelial disruption and exposure of underlying TF has been well documented in arterial
thrombosis [6, 15]; however, venous thrombosis typically occurs in the absence of gross
endothelial damage [7]. The cellular source of TF that contributes to venous thrombosis in
the absence of severe endothelial injury is not known. This study examined the role of
myeloid cell derived TF in a mouse model of venous thrombosis. Wild type mice that have
had TF inhibited by a monoclonal, rat anti-TF antibody (1H1) [17] and transgenic mice that
have reduced expression of TF in myeloid cells were utilized for this study. We used a
mouse electrolytic inferior vena cava model (EIM) which consistently stimulates thrombosis
in the presence of continuous blood flow that closely mimics clinical DVT [18, 19].
The objective of this study was to determine the contribution of myeloid cell TF to venous
thrombogenesis. We hypothesized that a reduction of myeloid cell TF would decrease
venous thrombogenesis in a mouse model of this disease.
Materials and Methods
Animals
Male C57BL/6 mice were obtained from Charles River Laboratories, Portage, Michigan
(n=30, mean body weight=24.7 g). Male transgenic mice deficient in TF in myeloid cells
(TFflox/floxLysMCre+ on a C57BL/6 background, n=51, mean body weight=25.9 g), and male
Cre negative littermate controls (TFflox/floxLysMCre-, n=35, mean body weight=26.8 g) [20,
21] were generated at University of North Carolina at Chapel Hill (UNC-CH) and shipped to
the University Michigan. Male mice were chosen for all groups because they produce a
larger and more consistent IVC thrombus than their female counterparts [22]. This study
was approved by the University of Michigan Committee on Use and Care of Animals and
conducted in accordance with The Guide for the Care and Use of Laboratory Animals [23],
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and the National Institutes of Health guidelines [24]. All animals were healthy and free of
specific pathogens. The University's animal program and facilities are accredited by the
Association for Assessment and Accreditation of Laboratory Animal Care, International. All
mice were group housed and non-acute mice were provided enrichment upon arrival (paper
bedding material or a plastic hut).
Animal model
We used the previously characterized electrolytic inferior vena cava model (EIM) to induce
thrombogenesis [18, 19, 22]. In brief, mice were anesthetized with an inhalation mixture of
5% isoflurane gas and 0.5L oxygen per minute and a surgical plane of anesthesia was
maintained with 2% isoflurane gas and 0.2L oxygen per minute. The inferior vena cava
(IVC) was exposed and all side branches, inferior to the level of the left renal vein but
superior to the iliac veins, were ligated using 7-0 Prolene (Ethicon, Inc, Somerville, NJ,
USA). A 30 gauge silver coated copper wire (KY-1-GRN, Electrospec, Dover, NJ, USA)
attached to a 25 gauge, 5mm stainless steel needle was placed into the caudal IVC and
positioned against the anterior wall (anode). Another needle (cathode) was placed
subcutaneously to complete the circuit. A current of 250 μAmps over 15 minutes was
applied using a Grass S48 square wave stimulator and a constant current unit (Grass
Technologies, An Astro-Med, Inc.,West Warwick, RI, USA). The EIM does not produce a
thermal injury in order to initiate thrombogenesis, but instead the current results in the
formation of free radicals that activates the IVC endothelial surface, thus promoting a
thrombogenic environment and subsequent thrombogenesis [18]. After the required amount
of time, needles were removed, the abdominal muscle and skin were closed, and the mouse
recovered. Non-thrombosed true controls (TC), that were surgically naïve animals, were also
utilized.
Animal groups
To determine the contribution of myeloid cell TF on early and later thrombosis in the
macrovasculature, the following experimental groups were studied. TFflox/floxLysMCre+
EIM (n=40), TFflox/floxLysMCre+ true control (n=11), TFflox/floxLysMCre- EIM (n=26),
TFflox/floxLysMCre-true controls (n=9). Mice expressing Cre recombinase under control of
lysozyme (LysM) promoter were backcrossed 6 generations onto the C57BL/6 background
[20, 21]. A sub-set of C57BL/6 mice (n=15 per group), received either 20 mg/kg of body
weight rat anti-mouse TF monoclonal antibody 1H1 [17] or 20 mg/kg of body weight rat
IgG control (Sigma-Aldrich, St. Louis, MO, USA) injected into the intraperitoneal (IP)
space (100 μL total), 24 hours prior to EIM procedure. Mouse groups were evaluated at the
following time points: day 2 and day 6 post EIM. Animals underwent the following
analyses: thrombus and IVC weight, vein wall morphometrics, vein wall gene expression by
quantitative Real-time PCR (qRT-PCR) for TF and β-actin, and plasma D-dimer levels
[Table 1].
Total Thrombus Weight (TW)
In brief, groups of mice were analyzed for (wet) total thrombus weight (TW) at the time of
euthanasia, in which the IVC thrombus and its associated vein wall were removed and
weighed in grams (g) [25]. The thrombus was then dissected from the IVC and the IVC was
used to assess vein wall expression of TF mRNA (see below).
Vein Wall Morphometrics
In selected samples the IVC, along with the aorta, were removed, paraffin-embedded, 4 μm
sections onto slides, and stained with hematoxylin and eosin (H&E). Slides were examined
under oil immersion light microscopy. Five representative high-power fields (5HPFs)
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around the vein wall were examined under high power (100×) and cell counts were
averaged. Cells were identified as neutrophils or monocytes on the basis of standard
histological criteria including nuclear size, cytoplasmic content, and total cell size in a
blinded fashion by a board-certified veterinary pathologist. Results from all 5HPFs were
added together and the mean ± standard error of the mean (SEM) was calculated for all vein
segments per animal group and time point [25, 26].
Quantitative (Real-time) polymerase chain reaction (qRT-PCR)
Gene expression of TF and β-actin was determined as follows: Vein wall segments,
separated from their respective thrombi, were placed in a 15 mL conical tube containing 1.5
mL of TRIzol (Invitrogen, Carlsbad, CA, USA) and then homogenized and RNA extracted
according to the manufacturer's recommendations. The concentration of total RNA was
determined using a Nanodrop spectrophotometer (Thermo Fisher Scientific Inc.,
Wilmington, DE, USA). Five μg of vein total RNA was reverse transcribed using-MMLV as
the reverse transcribing enzyme and oligo (dT) as the primer. The cDNA concentration was
determined using a Nanodrop spectrophotometer. cDNA was diluted to 22 ng/μL and used
as a template for Real-time PCR reaction. Real-time PCR was set up as a 25 μL reaction
using 12.5 μL of 2× RT2 Real-time Sybr Green PCR Master Mix, 1.0 μL of 22 ng/μL
cDNA, 1.0 μL of RT2 qPCR TF primer (band size 92bp, reference position 958; F3
PPM05163A) and β-actin (Actb, band size 154bp, reference position 182; PPM02945A)
primers from SABiosciences (Frederick, MD, USA). The reaction was run at 95°C for 10
min via 40 cycles of (95°C, 15 sec 60°C, 60 sec) in a Corbett Rotocycler (Corbett Research
Mortlake, New South Wales, Australia). Relative mRNA expression was calculated by the
formula 2- (Ct target gene −Ct reference gene) and cycle lengths used within the exponential phase
of the PCR.
D-dimer assay
Mice were anesthetized and a 500 μL blood sample was collected via cardiocentesis using a
syringe primed with 50 μL of sodium citrate 0.1 M (10:1 respectively). The citrated blood
was transferred into a 1.5 mL eppendorf and placed on a blood rocker until platelet poor
plasma (PPP) preparation. PPP was obtained by centrifuging blood at 1,500 g for 15 minutes
at 4°C. The plasma was then divided into 60 μL aliquots, immediately frozen in liquid
nitrogen (-196°C) and stored at -80°C until analysis. Plasma D-dimer was quantitated
according to manufacturer's recommendations by a sandwich-type ELISA from
Asserachrom D-dimer (Diagnostica Stago Inc., Mount Olive, NJ, USA). The D-dimer
activity was reported in ng/mL.
Statistical analysis
Statistical analysis included the mean ± SEM for each group. Statistical significance
between animal groups and time points were calculated using Analysis of Variance
(ANOVA) and unpaired t-test with Welch's Correction (GraphPad Software, Inc., La Jolla,
CA, USA). Significance was defined as p≤0.05. The extreme studentized deviate test
(Grubbs's test) was used to determine significant outliers to alpha=0.05 in groups of
continuous data. Outliers identified were not included in statistical analysis.
Results
Tissue factor derived from myeloid cells does not contribute to venous thrombosis in mice
Mice given a TF inhibitory antibody (1H1) had significantly smaller thrombi at 2 days post
thrombosis compared to mice given a rat IgG antibody control [Figure 1A]. No difference in
thrombus size was seen between the two groups at 6 days post thrombosis [Figure 1A]. In
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contrast to the results with the anti-TF antibody, deletion of the TF gene in myeloid cells did
not affect thrombosis at either 2 or 6 days post thrombosis (2 day: 189.1 ± 26.39 ×10-4 g vs.
157.7 ± 19.98 ×10-4 g, p=0.3569; 6 day: 199.4 ± 19.93 ×10-4 g vs. 179.6 ± 19.94 ×10-4 g,
p=0.4919) [Figure 1B].
Vein Wall Morphometrics—A significant increase was observed in neutrophil migration
through the vein wall at 2 days post thrombosis in both LysMCre groups compared to their
respective TC (LysMCre positive: 11.10 ± 1.571 cells/ 5 HPFs vs. 0.4800 ± 0.1306 cells/
5HPFs, p < 0.0001; LysMCre negative: 21.00 ± 7.805 cells/ 5 HPFs vs. 0.2857 ± 0.1253
cells/5HPFs, p=0.0199). There was a significant decrease in neutrophil migration through
the vein wall at 6 days in both groups compared to day 2 post thrombosis (LysMCre
positive: 4.420 ± 0.6055 cells/ 5 HPFs vs. 11.10 ± 1.571 cells/5HPFs, p=0.0002; LysMCre
negative: 2.800 ± 0.6340 cells/ 5 HPFs vs. 21.00 ± 7.805 cells/5HPFs, p=0.0370). There
were no significant differences between LysMCre negative and LysMCre positive mice at
any time points [Figure 2A].
There was a significant increase in monocyte migration through the vein wall at 2 days post
thrombosis in both groups compared to their respective TC (LysMCre positive: 4.020 ±
0.4811Cells/ 5 HPFs vs. 0.9600 ± 0.2344Cells/5HPFs, p < 0.0001; LysMCre negative: 3.733
± 0.8478Cells/ 5 HPFs vs. 0.5714 ± 0.2912Cells/5HPFs, p=0.0026). A significant increase
in vein wall monocyte migration was found at 6 days post thrombosis in the LysMCre
negative group, and a trending increase in the LysMCre positive group, compared to day 2
post thrombosis (LysMCre positive: 5.408 ± 0.5773Cells/ 5 HPFs vs. 4.020 ± 0.4811Cells/
5HPFs, p=0.0679; LysMCre negative: 8.733 ± 1.655Cells/ 5 HPFs vs. 3.733 ± 0.8478Cells/
5HPFs, p=0.0141). There were no significant differences between LysMCre negative and
LysMCre positive mice at any time points [Figure 2B].
The absence of tissue factor in myeloid cells does not affect vein wall expression of tissue
factor
No significant differences were observed in vein wall TF mRNA expression between
LysMCre positive mice and their littermate controls (LysMCre negative mice) at any time
point (Figure 3). Both groups showed a significant decrease in vein wall TF mRNA between
the TC and 2 days post thrombosis (LysMCre positive: 0.1348 ± 0.01044 units normalized
to β-actin vs. 0.0340 ± 0.005659 units normalized to β-actin, p < 0.0001; LysMCre
negative: 0.1288 ± 0.01078 units normalized to β-actin vs. 0.0252 ± 0.002711 units
normalized to β-actin, p=0.0026) before increasing at day 6. In addition, both the
LysMCre negative and positive mice showed a significant increase in vein wall TF mRNA
levels between 2 and 6 day post thrombosis (LysMCre positive: 0.0340 ± 0.005659 units
normalized to β-actin vs. 0.0782 ± 0.007790, p=0.0004; LysMCre negative: 0.0252 ±
0.002711 units normalized to β-actin vs. 0.1163 ± 0.01658, p=0.0004) [Figure 3].
Plasma D-dimer Levels
Increases in circulating plasma D-dimer (fibrin degradation product) concentration can serve
as an indication to active fibrinolysis post thrombosis. Evaluating LysMCre positive versus
LysMCre negative animals showed no significant differences in D-dimer levels at any time
point. Looking at temporal differences within the groups, both LysMCre positive and
LysMCre negative mice had significant increases in plasma D-dimer levels between TC and
2 days post thrombosis. (LysMCre positive: 69.13 ± 8.247ng/mL vs. 155.4 ± 15.75ng/mL,
p=0.0004; LysMCre negative: 59.25 ± 5.082ng/mL vs. 169.1 ± 2.173ng/mL, p=0.0025). In
turn, there was a significant decrease in plasma D-dimer levels from 2 to 6 days post
thrombosis (LysMCre positive: 155.4 ± 15.75ng/mL vs. 76.14 ± 5.097ng/mL, p=0.0007;
LysMCre negative: 169.1 ± 2.173ng/mL vs. 70.70 ± 7.466ng/mL, p=0.0062) [Figure 4].
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These findings demonstrate that peak fibrinolysis occurred 2 days post venous thrombosis in
these animals.
Discussion
TF is important in venous thrombosis of the macrovasculature. Mice that had circulating and
vascular wall TF inhibited by the use of a monoclonal, anti-mouse TF antibody (1H1) [17],
had a significant decrease in total thrombus weight as documented at 2 day post thrombosis,
compared to controls given rat IgG. This experiment showed that blocking TF, significantly
decreases acute venous thrombus formation, and that TF is important to acute venous
thrombogenesis in our animal model. There was no significant difference seen at day 6,
suggesting that TF does not significantly contribute to propagation of thrombosis between
day 2 and 6 post thrombosis. This finding is not unexpected since TF is thought to be
involved in the initiation and acute stages of venous thrombosis [5, 6]. Other studies have
also demonstrated the importance of TF in thrombus initiation using anti-TF antibody
inhibition [4, 16, 27].
In the LyMCre positive mice that are TF deficient in myeloid cells, there was no effect on
thrombus formation and total weight, versus their littermate controls (LysMCre negative
mice). This led to the conclusion that in the thrombosis of DVT, myeloid cell derived TF has
no contribution to venous thrombosis 2 and 6 days post-procedure. Thus TF from a non-
myeloid source, most likely the vein wall, is the major contributor to venous thrombosis in
this model. This finding is supported by other studies looking at the source of TF in venous
thrombosis. Using a mouse IVC ligation model, Day et al. showed that mice with low levels
of TF in hematopoietic cells developed a thrombus similar in size to the wild type controls.
However, mice with low expression of TF in the vessel wall, regardless of hematopoietic
cell expression, had significantly smaller thrombi [6]. Their conclusion was that TF is
important in venous thrombosis and that hematopoetic cells were not a major source [6]. In
our thrombosis model, the EIM needle is introduced into the lumen of the vein wall prior to
electrolytic endothelial cell activation and injury. This process combined with electrolytic
stimulation, could promote the exposure of vessel wall TF and other pro-inflammatory
mediators like vein wall P-selectin, interleukin-1β, circulating P-selectin, in concert leading
to the initiation of venous thrombogenesis as demonstrated by Alvarado et al. [22].
Thrombus formation initiates a local inflammatory response [28, 29]. During the acute
stages of inflammation, neutrophils are the predominant cellular responder. Over time,
monocytes increase at the site of thrombosis and are important in proteolytic digestion and
resolution of the thrombus components [30-33]. Previous experience with venous
thrombosis in our laboratory has shown that neutrophil migration through the vein wall
increases early in thrombosis development (6 hour and 2 day), with a rapid decline over
time. In contrast, monocytes have been shown to gradually increase with chronicity,
surpassing neutrophil levels by day 6 [22, 25, 34, 35]. Using morphometric analysis of
inflammatory cell migration through the vein wall during thrombosis, we demonstrated this
acute to chronic inflammatory pattern in both the LysMCre positive and LysMCre negative
mouse groups in this study. With regards to neutrophil migration, LysMCre positive and
LysMCre negative mice both had a peak in neutrophil migration to the site of thrombosis at
day 2 post thrombosis, followed by a significant decrease by day 6. In contrast, monocytes
showed a gradual, but significant increase in migration at days 2 and day 6 post thrombosis,
compared to non-thrombosed true controls. The peak in vein wall monocyte extravasation
occurred at 6 days post thrombosis. Similar vein wall inflammatory cell extravasation
patterns in wild type mice have been reported in both complete stasis induced and recent
flow models of venous thrombosis [18, 19, 22, 25, 26]. Thus, the findings in this study
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suggest that myeloid cell TF is not required for promoting vein wall neutrophil and
monocyte extravasations post venous thrombosis.
TF is constitutively expressed in the vein wall [36-38]. We quantified vein wall expression
of TF mRNA at different stages of thrombosis. Both, LysMCre positive and LysMCre
negative mice had a significant decrease in vein wall TF mRNA expression at day 2 post-
EIM compared to TC before increasing at day 6 post-EIM [Figure 3]. We postulate that the
TC value of TF mRNA in the vein wall represents the steady-state for TF expression in
these cells. The decrease in vein wall TF mRNA at day 2 post-EIM may represent negative-
feedback regulation of TF gene expression. Interestingly, a recent study [39] found that TF
expression was down-regulated in cutaneous wounds.
D-dimer is a product of plasmin degradation of cross-linked fibrin [40]. D-dimer levels are
elevated in initial thrombus formation [41] and serve as an indicator of fibrinolysis [42]. In
this study D-dimer levels were used as a supporting indicator of thrombus development and
resolution. In opposition to TF, which is important in thrombus initiation [4-6], D-dimer
plasma levels increase at later time points in thrombosis, during fibrinolysis [42] and
thrombus resolution. We showed that, both the LysMCre positive and LysMCre negative
mice showed a peak in D-dimer levels at day 2 post thrombosis, which decreased to baseline
levels by day 6, despite a large thrombus burden. This suggests that there is no active
fibrinolysis occurring at day 6.
The study described focuses on the cellular contribution and role of tissue factor in and EIM
of DVT formation in healthy mice. Although the EIM produces a DVT in the macrovascular
without complete occlusion of the vessel, which is similar to the clinical picture in humans,
there are some limitations to this model. In the mouse model, the DVT is created in the
inferior vena cava with side branches ligated to maximize thrombus formation and size;
however, in humans DVT is typically in a vein with different pathophysiologic features [18,
19]. These differences are examples of the inherent variables associated with use of animal
models for human disease. The EIM is a well characterized venous thrombosis model which
has the components of endothelial activation, blood stasis to some degree, and emphasizes
the continuation of flow during thrombus formation. These elements are commonplace to
clinical DVT. The findings in this study are important to understand the pathogenesis of
DVT. Development of DVT in humans has been linked to numerous predisposing factors,
such as malignant hematologic disorders, which may involve TF.
In conclusion, inhibition of all sources of TF with a mouse anti-TF antibody (1H1) showed
that TF promotes early venous thrombus formation mouse thrombosis model. However,
myeloid cell derived TF does not contribute to early venous thrombogenesis. This suggests
that the vessel wall is the major source of TF that leads to venous thrombus.
Acknowledgments
Research supported by NIH grant 1K01HL080962-01A2 (DDM) and HL-006350 (NM). We also would like to
thank the University of Michigan Medical School, Unit for Laboratory Animal Medicine for sponsoring the
comparative medicine training program for Dr. Anna Hampton.
References
1. Heit JA, Cohen AT, Anderson FA. Group VTEIA. Estimated annual number of incident and
recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood. 2005;
106:267A–A.
2. Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arterioscler
Thromb Vasc Biol. 2009; 29:298–310. [PubMed: 19228602]
Hampton et al. Page 7













3. Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb
Vasc Biol. 2008; 28:370–2. [PubMed: 18296591]
4. Himber J, Wohlgensinger C, Roux S, Damico LA, Fallon JT, Kirchhofer D, et al. Inhibition of
tissue factor limits the growth of venous thrombus in the rabbit. J Thromb Haemost. 2003; 1:889–
95. [PubMed: 12871353]
5. Nagai M, Yilmaz CE, Kirchhofer D, Esmon CT, Mackman N, Granger DN. Role of coagulation
factors in cerebral venous sinus and cerebral microvascular thrombosis. Neurosurgery. 2010;
66:560–5. discussion 5-6. [PubMed: 20124931]
6. Day SM, Reeve JL, Pedersen B, Farris DM, Myers DD, Im M, et al. Macrovascular thrombosis is
driven by tissue factor derived primarily from the blood vessel wall. Blood. 2005; 105:192–8.
[PubMed: 15339841]
7. Owens AP 3rd, Mackman N. Tissue factor and thrombosis: The clot starts here. Thromb Haemost.
2010; 104:432–9. [PubMed: 20539911]
8. Greeno EW, Bach RR, Moldow CF. Apoptosis is associated with increased cell surface tissue factor
procoagulant activity. Lab Invest. 1996; 75:281–9. [PubMed: 8765328]
9. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human
tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol. 1989; 134:1087–97.
[PubMed: 2719077]
10. Ranganathan G, Blatti SP, Subramaniam M, Fass DN, Maihle NJ, Getz MJ. Cloning of murine
tissue factor and regulation of gene expression by transforming growth factor type beta 1. J Biol
Chem. 1991; 266:496–501. [PubMed: 1985911]
11. Pawlinski R, Tencati M, Holscher T, Pedersen B, Voet T, Tilley RE, et al. Role of cardiac myocyte
tissue factor in heart hemostasis. J Thromb Haemost. 2007; 5:1693–700. [PubMed: 17663739]
12. Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of
tissue factor. Thromb Haemost. 1991; 66:67–79. [PubMed: 1833852]
13. Chou J, Mackman N, Merrill-Skoloff G, Pedersen B, Furie BC, Furie B. Hematopoietic cell-
derived microparticle tissue factor contributes to fibrin formation during thrombus propagation.
Blood. 2004; 104:3190–7. [PubMed: 15280200]
14. Mackman N. Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol Dis. 2006;
36:104–7. [PubMed: 16466951]
15. Wang L, Miller C, Swarthout RF, Rao M, Mackman N, Taubman MB. Vascular smooth muscle-
derived tissue factor is critical for arterial thrombosis after ferric chloride-induced injury. Blood.
2009; 113:705–13. [PubMed: 18931346]
16. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, et al. Blood-borne tissue factor:
another view of thrombosis. Proc Natl Acad Sci U S A. 1999; 96:2311–5. [PubMed: 10051638]
17. Kirchhofer D, Moran P, Bullens S, Peale F, Bunting S. A monoclonal antibody that inhibits mouse
tissue factor function. J Thromb Haemost. 2005; 3:1098–9. [PubMed: 15869619]
18. Diaz JA, Hawley AE, Alvarado CM, Berguer AM, Baker NK, Wrobleski SK, et al.
Thrombogenesis with continuous blood flow in the inferior vena cava. A novel mouse model.
Thromb Haemost. 2010; 104:366–75. [PubMed: 20589322]
19. Diaz JA, Wrobleski SK, Hawley AE, Lucchesi BR, Wakefield TW, Myers DD Jr. Electrolytic
Inferior Vena Cava Model (EIM) of Venous Thrombosis. Journal of visualized experiments :
JoVE. 2011
20. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I. Conditional gene targeting in
macrophages and granulocytes using LysMcre mice. Transgenic Res. 1999; 8:265–77. [PubMed:
10621974]
21. Pawlinski R, Wang JG, Owens AP 3rd, Williams J, Antoniak S, Tencati M, et al. Hematopoietic
and non-hematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice.
Blood. 2010
22. Alvarado CM, Diaz JA, Hawley AE, Wrobleski SK, Sigler RE, Myers DD Jr. Male mice have
increased thrombotic potential: Sex differences in a mouse model of venous thrombosis. Thromb
Res. 2011; 127:478–86. [PubMed: 21296387]
23. Institute of Laboratory Animal Resources (U.S.). Guide for the care and use of laboratory animals.
7th. Washington, D.C.: National Academy Press; 1996.
Hampton et al. Page 8













24. Welfare NIoHUSOoLA. Publich Health Service policy on humane care and use of laboratory
animals. Rev. August, 2002. Bethesda, MD: Office of Laboratory Animal Welfare, National
Institutes of Health; 2002.
25. Myers D Jr, Farris D, Hawley A, Wrobleski S, Chapman A, Stoolman L, et al. Selectins influence
thrombosis in a mouse model of experimental deep venous thrombosis. J Surg Res. 2002;
108:212–21. [PubMed: 12505044]
26. Wakefield TW, Strieter RM, Wilke CA, Kadell AM, Wrobleski SK, Burdick MD, et al. Venous
thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and
adhesion molecules. Arterioscler Thromb Vasc Biol. 1995; 15:258–68. [PubMed: 7749835]
27. Anthoni C, Russell J, Wood KC, Stokes KY, Vowinkel T, Kirchhofer D, et al. Tissue factor: a
mediator of inflammatory cell recruitment, tissue injury, and thrombus formation in experimental
colitis. J Exp Med. 2007; 204:1595–601. [PubMed: 17562818]
28. Saha P, Humphries J, Modarai B, Mattock K, Waltham M, Evans CE, et al. Leukocytes and the
natural history of deep vein thrombosis: current concepts and future directions. Arterioscler
Thromb Vasc Biol. 2011; 31:506–12. [PubMed: 21325673]
29. Wakefield TW, Henke PK. The role of inflammation in early and late venous thrombosis: Are
there clinical implications? Semin Vasc Surg. 2005; 18:118–29. [PubMed: 16168886]
30. Henke PK, Varga A, De S, Deatrick CB, Eliason J, Arenberg DA, et al. Deep vein thrombosis
resolution is modulated by monocyte CXCR2-mediated activity in a mouse model. Arterioscler
Thromb Vasc Biol. 2004; 24:1130–7. [PubMed: 15105284]
31. Humphries J, McGuinness CL, Smith A, Waltham M, Poston R, Burnand KG. Monocyte
chemotactic protein-1 (MCP-1) accelerates the organization and resolution of venous thrombi. J
Vasc Surg. 1999; 30:894–9. [PubMed: 10550187]
32. Ali T, Humphries J, Burnand K, Sawyer B, Bursill C, Channon K, et al. Monocyte recruitment in
venous thrombus resolution. J Vasc Surg. 2006; 43:601–8. [PubMed: 16520180]
33. Laouar A, Bauvois B. Characterization and modulation of cell surface proteases on human
myeloblastic (HL-60) cells and comparison to normal myeloid cells. Immunol Lett. 1992; 34:257–
65. [PubMed: 1362567]
34. Myers DD Jr, Rectenwald JE, Bedard PW, Kaila N, Shaw GD, Schaub RG, et al. Decreased
venous thrombosis with an oral inhibitor of P selectin. J Vasc Surg. 2005; 42:329–36. [PubMed:
16102635]
35. Henke PK, Mitsuya M, Luke CE, Elfline MA, Baldwin JF, Deatrick KB, et al. Toll-like receptor 9
signaling is critical for early experimental deep vein thrombosis resolution. Arterioscler Thromb
Vasc Biol. 2011; 31:43–9. [PubMed: 20966396]
36. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human
tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol. 1989; 134:1087–97.
[PubMed: 2719077]
37. Greeno EW, Bach RR, Moldow CF. Apoptosis is associated with increased cell surface tissue
factor procoagulant activity. Lab Invest. 1996; 75:281–9. [PubMed: 8765328]
38. Ranganathan G, Blatti SP, Subramaniam M, Fass DN, Maihle NJ, Getz MJ. Cloning of murine
tissue factor and regulation of gene expression by transforming growth factor type beta 1. J Biol
Chem. 1991; 266:496–501. [PubMed: 1985911]
39. McDonald AG, Yang K, Roberts HR, Monroe DM, Hoffman M. Perivascular tissue factor is
down-regulated following cutaneous wounding: implications for bleeding hemophilia. Blood.
2008; 111:2046–8. [PubMed: 18055866]
40. Pizzo SV, Schwartz ML, Hill RL, McKee PA. The effect of plasmin on the subunit structure of
human fibrin. J Biol Chem. 1973; 248:4574–83. [PubMed: 4268861]
41. Speiser W, Mallek R, Koppensteiner R, Stumpflen A, Kapiotis S, Minar E, et al. D-dimer and TAT
measurement in patients with deep venous thrombosis: utility in diagnosis and judgement of
anticoagulant treatment effectiveness. Thromb Haemost. 1990; 64:196–201. [PubMed: 2125371]
42. Janssen MC, Verbruggen H, Wollersheim H, Hoogkamer B, van Langen H, Novakova IR. D-dimer
determination to assess regression of deep venous thrombosis. Thromb Haemost. 1997; 78:799–
802. [PubMed: 9268174]
Hampton et al. Page 9














EIM electrolytic inferior vena cava model
IVC inferior vena cava
DVT deep vein thrombosis
TW thrombus weight
TF tissue factor
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Figure 1A and Figure 1B. Thrombus Weight Composite
* indicate significant differences, vs. non-thrombosed true controls, **indicate significant
differences, vs. 2 days post thrombosis (1A: n=10 for 2D thrombosis and n=5 for 6D
thrombosis; 1B: n=6 for TC, n=10 for 2D and 6D thrombosis). TC=Non-thrombosed true
controls, D=days post thrombosis. Systemic inhibition of tissue factor significantly
decreased thrombus size at 2 days post thrombosis. LysMCre + mice showed no decrease in
thrombus size at any time point, compared to LysMCre - littermate controls. Tissue factor
derived from myeloid cells did not contribute to thrombus size.
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Figure 2A and Figure 2B. Vein Wall Morphometrics Composite
average cell counts for each group (LysMCre +: n=5 for TC, n=10 for 2D and 6D
thrombosis; LysMCre -: n=3 for all groups). TC=Non-thrombosed true controls, D=days
post thrombosis, HPF=High power field. Both groups of mice (LysMCre + and LysMCre -)
showed the same acute (neutrophil) to chronic (monocyte) inflammatory pattern. No
differences were seen between the groups at any time-points.
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Figure 3. Tissue Factor Quantitative (Real-time) PCR
*indicate significant differences, vs. non-thrombosed true controls and 6 days post
thrombosis. (n=6 for TC, n=10 for 2D and 6D thrombosis). TC=Non-thrombosed true
controls, D=days post thrombosis. There were no differences in vein wall TF mRNA levels
between the LysMCre groups. LysMCre + mice showed no change in vein wall expression
of tissue factor.
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Figure 4. Plasma D-dimer
* indicate significant differences, vs. non-thrombosed true controls and 6 days post
thrombosis. (LysMCre +: n=5 for TC, n=10 for 2D and 6D thrombosis; LysMCre -: n=3 for
all groups). TC=Non-thrombosed true controls, D=days post thrombosis. LysMCre + and
LysMCre - mice showed a peak in D-dimer levels at day 2 which returned to baseline levels
by day 6 post thrombosis. The peak fibrinolysis occurred 2 days post venous thrombosis in
both LysMCre groups.
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